- The acute effects of microdosing psilocybin were more intense for participants who identified their active dosing condition, demonstrating a significant difference compared to the placebo.
- Despite the subjective effects, there was no substantial evidence to support improvements in well-being, creativity, or cognitive function due to microdosing.
- Expectations likely influenced the perceived benefits of microdosing, underscoring the role of psychological factors over pharmacological effects.
Overview of Microdosing with Psilocybin
The increasing interest over using small doses of psychedelics for cognitive enhancement has attracted both public and scientific attention. Although serotonergic psychedelics, like psilocybin, may produce significant changes in behavior, personality, and mental health, the effects of microdoses specifically lacked robust scientific examination until now. Individuals often microdose psychedelics as a self-medication strategy for conditions such as cluster headaches, depression, and anxiety. However, microdosing practices are largely unregulated and vary widely in methodology.
The common dosing schedule followed in microdosing typically consists of one dosing day followed by two days without a dose. While many anecdotal reports suggest mood, creativity, and cognitive enhancements from microdosing, controlled studies have highlighted that the effects could sometimes contradict expected outcomes. Some existing literature points to unverified benefits that can stem from psychological expectations rather than actual cognitive changes caused by the substances themselves.
Study Methodology
The current study involved 34 participants who were already interested in microdosing with psilocybin mushrooms (Psilocybe cubensis). Recruitment was conducted through social media and workshops. Participants were assessed using a double-blind, placebo-controlled design over two weeks, wherein individuals alternated between taking an active dose (0.5g of dried mushrooms) and a placebo. Blinding was not performed by the participants themselves, and all necessary ethical approvals were obtained prior to the start of the study.
Self-report measures and tasks assessing personality, anxiety, cognition, and mood were administered during the study. Specifically, various questionnaires were implemented to gauge participant expectations of change across different dimensions. Furthermore, physiological measurements like EEG recordings were conducted to examine brain activity shifts associated with the microdosing. The researchers utilized rigorous pre-processing methods to ensure the integrity of the EEG data.
Key Findings and Results
Analysis of the gathered data showed that participants who were able to identify their experimental condition experienced significantly heightened effects while under the influence of the psilocybin. However, despite these subjective effects, statistical analyses indicated no significant differences in terms of cognitive performance, creativity tests, or well-being measures between the microdosing and placebo conditions. Particularly, all results were consistent with the hypothesis that prior expectations may have driven perceived changes rather than the pharmacological effects of the microdosing itself.
While there was a notable decrease in theta band activity in the EEG analysis post-administration of the psilocybin, this finding did not translate to enhanced cognitive function or mental health benefits. Additionally, the overall assessments revealed no significant changes in physical activity levels. Consequently, the researchers concluded that their findings align with concerns about the anecdotal claims surrounding microdosing, suggesting that the subjective effects observed may be primarily attributed to psychological expectations rather than actual therapeutic benefits.
Final Thoughts
This study significantly contributes to the body of research by rigorously evaluating the impacts of microdosing psilocybin in controlled settings. While the active dose elicited subjective effects, it clearly demonstrated no meaningful improvements in creativity, cognition, or well-being. They emphasized the need for further research to understand longer-term effects of microdosing protocols and examine cumulative impacts over extended periods to clarify the potential implications better. Overall, their results cast skepticism on the purported benefits of microdosing while affirming the necessity for more scientific scrutiny into historical claims surrounding psychedelic substances.
Read the full paper summary on Blossom.

